Background: Thrombolytic therapy improves the functional outcome in acute ischemic stroke, but the risk of death and cerebral hemorrhage remains high. Aspirin given together with a thrombolytic agent may worsen the risk-to-benefit ratio. We performed a further Multicenter Acute Stroke Trial-Italy (MAST-I) which is the only randomized, controlled trial that has tested the effect of this combination to evaluate the risk of aspirin use plus streptokinase. Patients and Methods: We made a post hoc analysis of the MAST-I results comparing streptokinase plus aspirin (156 patients) with streptokinase alone (157 patients). We evaluated the risk of death and cerebral hemorrhage. Results: The combined regimen significantly increased early case fatality from day 3–10 (53 vs. 30; OR 2.1; CI 1.2–3.6). The death excess was solely due to treatments and was not explained by the main prognostic predictors (multifactorial analysis). The cause of death in the combination group was mainly cerebral (42 vs. 24; OR 2.0; CI 1.3–3.7) and associated with hemorrhagic transformation (22 vs. 11; OR 2.2; CI 1.0–5.0). The rate of stroke reoccurrence was not increased in patients treated with streptokinase alone (15 vs. 11; OR 1.4; CI 0.6–3.4). Conclusions: Stroke patients treated with streptokinase plus aspirin have an increased risk of early death, probably due to cerebral hemorrhagic complications. Whenever thrombolytics are chosen for acute stroke treatment, aspirin and other antiplatelet agents should be avoided.

Keywords:
Acute ischemic stroke, Streptokinase, Aspirin, Randomized controlled trial
1.
Caplan LR, Mohair JP, Kistler JP, Koroshetz W: Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis – not a panacea for ischemic stroke. N Engl J Med 1997;337:1309–1310.
2.
Grotta J: Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? T-PA – the best current option for most patients. N Engl J Med 1997;337:1310–1313.
3.
Bath P: Alteplase not yet proven for acute ischemic stroke. Lancet 1998;352:1238–1239.
4.
Anonymous: FDA approves t-PA for stroke. Lancet 1996;347:1822.
5.
Collins R, Peto R, Baigent C, Sleight P: Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847–860.
6.
Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W: Guidelines for thrombolytic therapy for acute ischaemic stroke: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1996;94:1167–1174.
7.
The European Ad Hoc Consensus Group: European strategies for early intervention in stroke. Cerebrovasc Dis 1996;6:315–324.
8.
American Academy of Neurology: Practice Advisory: Thrombolytic therapy for acute ischemic stroke – summary statement: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835–839.
9.
The Cooperative Acute Stroke Study (ECASS): Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017–1025.
10.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245–1251.
11.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
12.
The Multicenter Acute Stroke Trial-Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145–150.
13.
Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961–966.
14.
Multicentre Acute Stroke Trial-Italy Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509–1514.
15.
Motto C, Aritzu E, Boccardi E, De Grandi C, Piana A, Candelise L: Reliability of hemorrhagic transformation diagnosis in acute ischemic stroke. Stroke 1997;28:302–306.
16.
Rothman KJ, Greenland S, Walker AM: Concepts of interaction. Am J Epidemiol 1980;112:467–470.
17.
Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287–1294.
18.
Coller BS: Platelets and thrombolytic therapy. N Engl J Med 1990;322:33–42.
19.
Clark WM, Madden KP, Lyden PD, Zivin JA: Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 1991;22:872–876.
20.
Motto C, Ciccone A, Aritzu E, Boccardi E, De Grandi C, Piana A, Candelise L: Hemorrhage after an acute ischemic stroke. Stroke 1999;30:761–764.
21.
International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
22.
CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.